Saitama, Japan

Hiroaki Taguchi

This inventor holds 1 USPTO granted patent. Top assignee: Zeria Pharmaceutical Co., Ltd.. Active years: 2004.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroaki Taguchi. Retrieved from https://idiyas.com/inventor/hiroaki-taguchi-eq5xs7d7

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2004

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Hiroaki Taguchi: Innovator in Pharmaceutical Chemistry

Introduction

Hiroaki Taguchi is a notable inventor based in Saitama, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative drug formulations.

Latest Patents

Hiroaki Taguchi holds a patent for "Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same." This invention showcases his expertise in creating effective pharmaceutical compounds.

Career Highlights

Taguchi is associated with Zeria Pharmaceutical Co., Ltd., where he has been instrumental in advancing research and development efforts. His work has contributed to the company's reputation for innovation in the pharmaceutical industry.

Collaborations

Throughout his career, Hiroaki Taguchi has collaborated with esteemed colleagues such as Katsuo Shinozaki and Masakazu Murata. These partnerships have fostered a collaborative environment that enhances the quality of research and development.

Conclusion

Hiroaki Taguchi's contributions to pharmaceutical chemistry and his innovative patent demonstrate his commitment to advancing medical science. His work continues to impact the industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…